Companies · Software / Tech
IVYLAND · Software / Tech · refined from filed group “Other Technology”
Diligence memoA one-page analyst read on LifeLens Technologies, Inc. — recommendation, valuation, rhythm, risks.→LifeLens Technologies, Inc. looks fair against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
LifeLens Technologies, Inc. is one of 3920 Software / Tech companies tracked from IVYLAND. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.
Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 88% of sector peers (real $). Modeled value above 65% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #70 of 95.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Machina Labs, Inc. | Series B | $70.2M | $205.6M | 2.07× |
| Metaview Technologies Inc. | Series B | $51.7M | $198.0M | 2.00× |
| Felix Technologies Inc. | Series B | $61.1M | $194.6M | 1.96× |
| Foxglove Technologies Inc. | Series B | $58.0M | $190.8M | 1.92× |
| NetBox Labs, Inc. | Series B | $53.3M | $184.8M | 1.86× |
| Omni Design Technologies, Inc. | Series B | $34.3M | $182.7M | 1.84× |
| Alaffia Technology Solutions, Inc. | Series B | $57.3M | $182.6M | 1.84× |
| Rivington Labs Inc. | Series B | $59.6M | $176.4M | 1.78× |
| Labs Companies, Inc. | Series B | $57.5M | $175.4M | 1.77× |
| Reveal Technology, Inc. | Series B | $28.5M | $159.7M | 1.61× |
| Architect Financial Technologies Inc. | Series B | $52.5M | $158.8M | 1.60× |
| Pylon Labs, Inc. | Series B | $49.7M | $156.3M | 1.58× |
| LifeLens Technologies, Inc. this company | Series B | $39.6M | $70.3M | 0.71× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $2.9M | 2019-06-21 | $14.6M | $99.5M | 90% |
| Seed | $3.2M | 2020-07-20 | $16.0M | $106.3M | 90% |
| Series B | $18.4M | 2024-06-28 | $102.1M | $137.6M | 90% |
| Series B | $15.1M | 2025-11-04 | $83.8M | $70.3M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Todd Johnson | — | 26 other | 2024-06 |
| ROBERT SCHWARTZ | — | 20 other | 2019-06 |
| Daniel Sullivan | — | 6 other | 2019-06 |
| David Robins | — | 2 other | 2019-06 |
| Brian Robins | — | 1 other | 2019-06 |
| Brent Moen | — | — | 2025-11 |
| Felice Dilorio | — | — | 2025-11 |
| Gunnar Pah | — | — | 2024-06 |
| Henry Ristuccia | — | — | 2025-11 |
| Landy Toth | — | — | 2019-06 |
| Neil Muchin | — | — | 2020-07 |
| Neil Munchin | — | — | 2024-06 |
| Rick Buchholz | — | — | 2024-06 |
LifeLens Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Kollective Technology, Inc. | Software / Tech | Series A | $34.2M | $188.0M | network1 shared operator · same sector |
| Data Vault Holdings Inc. | Software / Tech | Series B | $39.0M | $67.2M | same sector · same stage |
| Biobot Analytics, Inc. | Software / Tech | Series B | $41.0M | $73.4M | same sector · same stage |
| Medicom Technologies, Inc. | Software / Tech | Series B | $42.1M | $74.5M | same sector · same stage |
| Miramar Labs, Inc. | Software / Tech | Series B | $45.6M | $75.1M | same sector · same stage |
| Patriot Software Co | Software / Tech | Series B | $46.3M | $75.9M | same sector · same stage |
| Sparta Software Corp | Software / Tech | Series B | $31.8M | $54.7M | same sector · same stage |
| Morpheus Data Holdings, LLC | Software / Tech | Series B | $30.8M | $63.5M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Lifelink Systems, Inc. | Software / Tech | Series A | $12.6M | 87% |
| Lifeloc Technologies, Inc | Software / Tech | Seed | $4.1M | 85% |
| Lifeswap Inc. | Other Technology | Seed | $6.7M | 84% |
| LifeSpot Technology, Inc. | Software / Tech | Pre-Seed | $6.5M | 83% |
| Lifegait, Inc. | Other Technology | Seed | $10.5M | 83% |
| Lifekey, Inc. | Other Technology | Pre-Seed | $6.4M | 83% |
| Lifescape LLC | Other Technology | Pre-Seed | $13.6M | 82% |
| LifeLabs Design, Inc. | Other Technology | Series A | $128.0M | 82% |
See where LifeLens Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at LifeLens Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.